Current Report Filing (8-k)
December 29 2015 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): December 28, 2015
Ekso Bionics Holdings, Inc.
(Exact
Name of Registrant as specified in its charter)
Nevada |
333-181229 |
99-0367049 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(203) 723-3576
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 – Other Events
On
December 28, 2015, Ekso Bionics Holdings, Inc. (the “Company”) consummated its previously announced registered direct
offering of 15,000 shares of Series A Convertible Preferred Stock and warrants to purchase 14,851,486 shares of the Company’s
common stock for gross proceeds of $15 million. The Company intends to use the proceeds for investments in clinical,
sales and marketing initiatives to accelerate adoption of the Ekso exoskeleton in the rehabilitation market, for research, development
and commercialization activities with respect to an Ekso robotic exoskeleton for home use, for the development and commercialization
of able-bodied exoskeletons for industrial use and for other general corporate purposes.
Forward-Looking Statements
This Current Report on Form 8-K contains
“forward-looking statements.” Any statements contained in this press release that do not describe historical facts
may constitute forward-looking statements. Forward-looking statements may include,
without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives
relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial
condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and
(iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because
they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and
are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements
as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements
or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability
to obtain adequate financing to fund the Company’s operations and necessary to develop or enhance our technology, the significant
length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad
market acceptance of the Company’s products, the failure of our sales and marketing organization or partners to market our products
effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain
patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical
devices, lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s
business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with
the SEC. These forward-looking statements are made as of the date of this Current Report, and the Company
does not undertake an obligation to update these forward-looking statements after such date.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC. |
|
|
|
|
|
By: /s/ Max Scheder-Bieschin |
|
Name: Max Scheder-Bieschin |
|
Title: Chief Financial Officer |
Dated: December 29, 2015
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024